Compare Enbridge Inc (ENB) vs Teladoc Health Inc (TDOC) Price & Performance

ENB trades at $45.89, down 1.4% on the day, with a bearish technical signal but strong recent earnings beats. The company posted $65.19B in 2025 revenue, with net income of $7.49B and a 7.34% margin. Analysts maintain a consensus buy rating with a $61.63 price target, highlighting a 6% dividend yield and robust cash flow from operations of $12.27B.

Outlook is positive due to consistent EBITDA growth, a $41B project backlog, and defensive midstream assets, though risks include high debt levels and sensitivity to interest rates. The stock offers value with a P/E of 25.54 and P/S of 1.73, supported by institutional interest and dividend stability.

Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.

TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.